Current approach to the acute management of cryptococcal infections

Journal of Infection

Volumn 41, Issue 1, 2000, Pages 18-22

  Powderly, W G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CLOTRIMAZOLE; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ARTICLE; CHEMOTHERAPY; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNIZATION; INFECTION PREVENTION; LUNG INFECTION; MYCOSIS; NONHUMAN;

EID: 0033848075     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0696     Document Type: Article

References (44)

1. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans
2. The evolution of pulmonary cryptococcosis: Clinical implications from a study of 41 patients with and without compromising host factors
3. Pulmonary cryptococcosis in HIV-negative patients: Recent experience
4. Cryptococcal meningitis and AIDS
5. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
6. Recent advances in the management of cryptococcal meningitis in patients with AIDS
7. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
8. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
9. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
10. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
11. Randomized double blind trial of Ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients
12. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
13. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS
14. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis
15. Randomized comparative trial of itraconazole and fluconazole for treatment of AIDS-related cryptococcal meningitis
16. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS
17. A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis
18. Early mycological treatment failure in AIDS-associated cryptococcal meningitis
19. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing
20. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis
21. The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis
22. Amphotericin-B resistant Cryptococcus neoformans in a patient with AIDS
23. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis
24. The hidden danger of primary fluconazole prophylaxis for patients with AIDS
25. A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
26. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
27. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
28. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
29. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy
30. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy
31. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy
32. USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
33. Opportunistic infections occuring during highly active antiretroviral treatment
34. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection
35. Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy
36. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
37. Treatment of cryptococcal meningitis with combination of amphotericin B and flucytosine for four as compared with six weeks
38. Idiopathic CD4 + T-lymphocytopenia - Four patients with opportunistic infections and no evidence of HIV infection
39. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group
40. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
41. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
42. 3: Demonstration of efficacy in a positive, multicenter trial
43. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study
44. HIV prophylaxis in an era of effective antiretroviral therapy